中国·腾博-www.tengbo9885.com|官网首发

中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.

科学论文
SCIENTIFIC PUBLICATION
  • 03.232022
    2018
    Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 9(1):5361. (*: Corresponding authors, PMCID: PMC6299138)Jia Q., Wu W., Wang Y., Alexander P.B., Sun C., Gong Z., Cheng J., Sun H., Guan Y.,
  • 03.232022
    Dr. Qi-Jing Li’s Publication
    Dr. Li has published more than 100 papers on Cell, Cancer Cell, Nature, Nature Immunology, Immunity, EMBO, and Nature Communication, etc. His publications have been cited for more than 9000 times. Below are some selected papers with significant impacts in the scientific field.
  • 03.232022
    Dr. Pin Wang’s Publication
    Dr. Wang has published more than 80 papers on Nature Biotechnology, Cell Stem Cell, PNAS, Nature Communication, ACS Nano, and Molecular Therapy, etc. He has also filed more than 10 patents as lead inventor or co-inventor. Below are some selected papers and patents with significant impacts in the scientific field.
12
查看更多
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
XML 地图